INTRODUCTION {#s1}
============

Gastric neuroendocrine carcinoma (GNEC), which accounts for 0.16 to 1.48% of all gastric cancers \[[@R1]--[@R3]\], is derived from gastric epithelial tissues and has the characteristics of neuroendocrine differentiation tumors. Given its low incidence, relevant studies on GNEC are limited. GNEC differs significantly from gastric adenocarcinoma (GAC) based on biological characteristics and pathological features. GNEC is more likely to be accompanied by vessel invasion, lymph node metastasis and distant metastasis, which indicate a poor prognosis. For treating GNEC, National Comprehensive Cancer Network (NCCN; 2014) guidelines also recommend radical resection and cleaning of lymph nodes around the stomach. Only a few studies on GNEC long-term outcomes with radical surgery have been conducted to date, limiting further exploration and treatment options for this rare and highly malignant neoplasm. In this study, we analyzes differences in long-term outcomes after radical surgery between a GNEC group and a GAC group based on propensity score matching (PSM) and evaluated impact factors influencing the different outcomes.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The clinicopathological parameters of all patients (*n* = 3189) are outlined in Table [1](#T1){ref-type="table"}. The proportions of male gender, tumor size, T stage, lymph node metastasis rate and total gastrectomy in the GNEC group were increased compared with the GAC group, whereas average American Society of Anesthesiologists (ASA) scores were reduced. In total, 97 GNEC and 194 GAC patients were selected by a 1:2 PSM. Differences in the clinicopathological parameters of post-matched samples were not significant. Of the 97 GNEC cases, 25 were of the small cell type and 72 of the large cell type. The clinicopathological factors significantly associated with the prognosis of the 97 GNEC patients are listed in Table [2](#T2){ref-type="table"}.

###### Patient characteristics and treatment details

                         All Patients   Propensity-Matched Patients                         
  ---------------------- -------------- ----------------------------- ------- ----- ------- -------
  Age (year)                                                          0.114                 0.736
   \<65                  2057           59                                    114   59      
   ≥65                   1032           41                                    80    38      
  Gender                                                              0.001                 0.406
   Male                  2274           48                                    106   48      
   Female                815            52                                    88    49      
  ASA score                             0.005                                       0.874   
   1                     1901           46                                    84    45      
   2                     1015           44                                    94    44      
   ≥3                    173            10                                    16    8       
  Tumor size (cm)                                                     0.007                 0.392
   \<50                  1503           35                                    76    33      
   ≥50                   1586           65                                    118   64      
  T stage                                                             0.001                 0.247
  T1                     681            1                                     4     1       
  T2                     351            12                                    38    12      
  T3                     761            80                                    134   78      
  T4                     1296           7                                     18    6       
  N stage                                                             0.008                 0.332
  N0                     1075           22                                    50    20      
  N1                     2014           78                                    144   77      
  Operation types                                                     0.012                 0.131
  Total gastrectomy      1660           68                                    112   67      
  Distal gastrectomy     1368           29                                    80    29      
  Proximal gastrectomy   61             2                                     2     1       
  Surgical method                                                     0.052                 0.610
   Laparoscopic          2078           58                                    120   57      
   Open                  1011           42                                    74    40      

###### Univariate and multivariate analyses of variables for 97 GNEC patients

                                          Univariate analysis   Multivariate analysis                                     
  --------------------------- ----------- --------------------- ----------------------- ------- ----------- ------------- -------
  N                           97 (100%)                                                                                   
  Age                                                                                   0.727                             
  \<65                        59 (61%)    51.6                  38.5                                                      
  ≥65                         38 (39%)    59.4                  33.6                                                      
  Gender                                                                                0.499                             
  Male                        48 (49%)    56.2                  38.9                                                      
   Female                     49 (51%)    53.3                  37.1                                                      
  Location of tumor                                             0.071                                                     
   Upper                      49 (50%)    44.7                  31.9                                                      
   Middle                     25 (26%)    62.1                  44.1                                                      
   Lower                      23 (24%)    71.5                  52.1                                                      
  Classification                                                                        0.903                             
   Small cell                 25 (26%)    61.1                  46.0                                                      
   Large cell                 72 (74%)    52.4                  36.7                                                      
  Tumor diameter (cm)                     0.017                                                 0.438                     
  \<5                         35 (36%)    72.0                  60.2                                                      
  ≥5                          62 (64%)    45.3                  27.5                                                      
  pT                                                                                    0.09                              
   T1                         1 (1%)      100                   100                                                       
   T2                         12 (12%)    82.5                  78.6                                                      
   T3                         78 (81%)    49.4                  28.6                                                      
   T4                         6 (6%)      50.0                  50.0                                                      
  pN                                                                                    0.005                             
   N0                         20 (21%)    90.0                  57.6                            reference                 
   N1                         77 (79%)    45.3                  27.3                            3.494       1.352-9.031   0.010
  pTNM                                                                                  0.018                             0.852
   I                          1 (1%)      100                   100                                                       
   II                         19 (19%)    71.6                  57.3                                                      
   III                        77 (80%)    45.3                  27.8                                                      
  Chemotherapy                                                  0.000                                                     
  Yes                         44 (45%)    74.2                  58.9                            0.381       0.203-0.714   0.003
  No                          53 (55%)    37.3                  19.2                            reference                 
  Surgical approach                                             0.298                                                     
  LG\#                        57 (59%)    46.9                  35.7                                                      
  OG\#                        40 (41%)    64.5                  44.3                                                      
  NEC components                                                0.700                                                     
  \<70%                       42 (43%)    56.2                  39.9                                                      
  ≥70%                        55 (57%)    53.8                  37.2                                                      
  Mitotic count (/10 HPF\#)                                                             0.017                             0.151
  \<36                        57 (59%)    60.4                  46.1                                                      
  ≥36                         40 (41%)    44.8                  22.4                                                      
  Ki-67 (%)                                                                             0.004                             
  \<57.5%                     33 (34%)    68.0                  56.1                            reference                 
  ≥57.5%                      64 (66%)    48.7                  27.0                            2.384       1.131-5.025   0.022

\#: LG - laparoscopic gastrectomy, OG - open gastrectomy, NEC - gastric neuroendocrine carcinoma, HPF -- high-power field

Comparisons of overall and recurrence-free survival rates {#s2_2}
---------------------------------------------------------

The median follow-up periods were 47 and 48 months for the GNEC and GAC groups. Compared with the GAC group, both the 3-year survival (54.7% *vs*. 67.9%, *p* = 0.018) 5-year survival (38.7% *vs*. 51.8%, *p* = 0.030) rates of the GNEC group were poorer (Figure [1A](#F1){ref-type="fig"}). However, similar 3-year recurrence-free survival (RFS) (51.1% *vs*. 55.5%, *p* = 0. 628) and 5-year RFS (36.6% *vs*. 40.1%, *p* = 0. 345) rates were observed for both groups (Figure [1B](#F1){ref-type="fig"}).

![Comparison of OS **A.** and RFS **B.** curves for GNEC and GAC.](oncotarget-08-57495-g001){#F1}

Recurrence and treatment {#s2_3}
------------------------

There were 152 cases without recurrence and 139 cases with recurrence; the latter included 50 GNEC patients and 89 GAC patients. The recurrence rates of the two groups were similar (51.5% *vs*. 45.9%, *p* \> 0.05). The mean recurrence time was also similar between the groups (16.5 months *vs*. 18.7 months, *p* = 0.810). The types of recurrence for GNEC and GAC are presented in Figure [2](#F2){ref-type="fig"}. In the GNEC group, peritoneal recurrence was the most common type, followed by distant nodal metastasis, local recurrence and hematogenous metastasis. Peritoneal recurrence was also the most common type in the GAC group, followed by hematogenous metastasis, distant nodal metastasis and local recurrence. In addition, 40% (20/50) of the GNEC patients with recurrence received chemotherapy, and 35% (35/99) of the GAC patients with recurrence did not. No significant difference in the proportion receiving chemotherapy was noted between the groups (*p* \> 0.05).

![Recurrence types: **A.** overall recurrence types; **B.** recurrence types of GNEC; **C.** recurrence types of GAC.](oncotarget-08-57495-g002){#F2}

Analysis of postrecurrence survival (PRS) {#s2_4}
-----------------------------------------

The overall mean PRS was 10.4 months. As shown in Figure [3](#F3){ref-type="fig"}, there were significant differences in PRS between the GNEC and GAC groups (5.2 *vs*. 14.8 months, *p* \< 0.001), with the 1- and 2-year PRS rates of the GNEC group being reduced compared with the GAC group (14.0% *vs*. 37.7%, *p* \< 0.001; 0% *vs*. 20.9%, *p* = 0.002), and an improved PRS time was noted in patients who received chemotherapy after recurrence (13.9 *vs*. 9.8 months, *p* = 0.044). However, according to stratified analysis, PRS in the GNEC group was similar between patients who had received chemotherapy and those who had not (6.4 *vs*. 4.4 months, *p* = 0.202). Conversely, significant differences were noted in the GAC group (18.3 *vs*. 12.8 months, *p* = 0.049).

![Comparison of PRS curves for GNEC and GAC](oncotarget-08-57495-g003){#F3}

Prognostic value of the Ki-67 labeling index for GNEC {#s2_5}
-----------------------------------------------------

According to receiver operating characteristic (ROC) curve calculations, the sum of the sensitivity and specificity of the Ki-67 labeling index reached its maximum at a cut-off of 57.5%. The distribution of the Ki-67 labeling index is shown in Figure [4A](#F4){ref-type="fig"}. We divided GNEC patients into two groups: 33 cases with a low Ki-67 labeling index ( \< 57.5%) and 64 cases with a high Ki-67 labeling index ( ≥ 57.5%). As shown in Figure [4B](#F4){ref-type="fig"}, the 5-year overall survival (OS) of the high Ki-67 labeling index group was significantly reduced compared with that of the low Ki-67 labeling index group (27.0% *vs*. 56.1%, *p* = 0.004), as was the 5-year RFS (61.2% *vs*. 22.7%, *p* = 0.014). In addition, the recurrence rate of the high Ki-67 labeling index group was significantly increased compared with that of the low Ki-67 labeling index group (59.3% *vs*. 36.4%, *p* = 0.032), whereas the PRS of the high Ki-67 labeling index group was significantly greater than that of the low Ki-67 labeling index group (8.9 months *vs*. 4.0 months, *p* = 0.004).

![**A.** Distribution of the Ki-67 labeling index; **B.** relationship between the Ki-67 labeling index and GNEC patient survival time.](oncotarget-08-57495-g004){#F4}

Analysis of factors influencing the PRS of GNEC {#s2_6}
-----------------------------------------------

As listed in Table [3](#T3){ref-type="table"}, univariate and multivariate analyses indicated that the Ki-67 labeling index is an independent prognostic factor for GNEC patients with recurrence.

###### Prognostic factors for the PRS of 139 recurrence patients

                               Univariate analysis   Multivariate analysis                   
  ---------------------------- --------------------- ----------------------- --------------- -------
  Ages (year)                                        0.236                                   
  \<65                         86                                                            
   ≥65                         53                                                            
  Gender                                             0.710                                   
   Mal                         96                                                            
   Female                      43                                                            
  ASA score                    0.161                                                         
   1                           58                                                            
   2                           67                                                            
  ≥3                           14                                                            
  Tumor size (cm)                                    0.915                                   
   \<50                        42                                                            
   ≥50                         97                                                            
  T stage                                            0.767                                   
  T1                           0                                                             
  T2                           10                                                            
  T3                           114                                                           
  T4                           15                                                            
  N stage                                            0.274                                   
  N0                           17                                                            
  N1                           122                                                           
  Operation types                                    0.332                                   
  Totalgastrectomy             96                                                            
  Distal gastrectomy           40                                                            
  Proximal gastrectomy         3                                                             
  Surgical methods                                   0.626                                   
  Laparoscopic                 86                                                            
  Open                         53                                                            
  Ki-67 labeling index (%)                           0.000                                   0.000
  \<52.5                       76                                            1 (reference)   
  ≥52.5                        63                                                            
  Treatment after recurrence                         0.044                                   .062
  Chemotherapy                 55                                            1 (reference)   
  Best supportive care         84                                                            
  RFS                                                0.051                                   
   \<12 months                 58                                                            
  ≥12 months                   81                                                            

DISCUSSION {#s3}
==========

The incidence of GNEC is increasing, and the prognosis is poor \[[@R4]--[@R6]\]. Because GNEC easily infiltrates vessels and lymphatic vessels, the OS of GNEC is poorer than that of GAC \[[@R7]\]. Jiang et al. \[[@R3]\] reported that the 5-year survival rate of 42 large cell-type GNEC patients (31.1%) was reduced compared with 307 GAC patients (69.3%). Furthermore, when comparing tumor stages, the survival rate of stage I-IV GNEC was significantly worse than that of GAC. The present study found a markedly worse 5-year survival rate for the GNEC group (38.7%) compared to the GAC group (51.8%). Although our study revealed a similar RFS between the groups, the OS of the GNEC group was significantly lower, which might be related to the reduced PRS of these patients. Treatment of recurrence is an important factor influencing PRS \[[@R8], [@R9]\], and recurrence patients receiving chemotherapy and/or radiotherapy exhibited increased PRS rates compared with those who underwent best support treatment \[[@R10]\]. Nonetheless, no criteria are available regarding the treatment of recurrent GNEC. Based on the treatment criteria of small cell lung cancer, Okita et al. used a treatment based on a combination of cisplatin and irinotecan in patients with recurrent GNEC after radical resection, and the overall response to chemotherapy was 75% \[[@R11]\]. We adopted chemotherapy based on fluorouracil (5-Fu) to treat recurrent GNEC patients and found that the PRS of these patients who received chemotherapy was similar to that of patients who had not received chemotherapy. Indeed, the results indicated a lack of improved PRS in recurrent GNEC patients who received 5-Fu chemotherapy. This finding prompted us not to follow the treatment experiences of GAC for GNEC. However, combination treatment based on cisplatin and irinotecan as well as capecitabine in combination with temozolomide was able to improve the outcome of recurrent GNEC patients \[[@R11], [@R12]\].

The Ki-67 labeling index is related to GNEC recurrence and prognosis \[[@R13]--[@R15]\]. Boo et al. \[[@R16]\] demonstrated that a high Ki-67 labeling index and poor differentiation are closely related to tumor recurrence. Multivariate analysis indicated the Ki-67 labeling index to be the only independent prognostic factor. Our study showed an increased recurrence rate for the high Ki-67 labeling index group ( ≥ 57.5%) with reduced OS time. The prognosis of GNEC also appears to depend on a different type of chemotherapy schedule, targeted on the basis of Ki-67 value (more or less than 55%) \[[@R17]\]. Moreover, the Ki-67 labeling index is related to the chemotherapy outcome of metastatic or recurrent GNEC \[[@R18]\]. By analyzing data from 252 advanced gastrointestinal neuroendocrine tumor patients who were given chemotherapy, Sorbye found that the 30-month survival rate was 23% when the patients had a Ki-67 labeling index \< 55%, which was only 7% for those with a Ki-67 labeling index ≥ 55% \[[@R19]\]. Our study revealed a significantly reduced PRS for the high Ki-67 labeling index group compared with the low Ki-67 labeling index group and that the Ki-67 labeling index was an independent factor influencing the PRS of GNEC. As the results indicated that GNEC patients with a high Ki-67 labeling index have a higher propensity for recurrence, it is necessary to enhance follow-up surveillance and identify potential metastasis and recurrence as soon as possible.

To the best of our knowledge, this is the first study adopting PSM to compare the outcome of radical resection in GNEC and GAC patients. The offset is unavoidable, although we selected the PSM. Therefore, it is necessary to further evaluate the outcome of radical surgery for GNEC using high-quality, multi-center prospective trials.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

This study was a retrospective analysis of prospectively maintained clinical pathologic data derived from 100 GNEC patients and 3089 GAC patients at the Department of Gastric Surgery, Fujian Medical University Union Hospital between January 2006 and December 2013. Two groups were matched for gender, age, ASA score, operative period, tumor size and T and N stages. In total, 97 GNEC patients and 194 GAC patients were included using 1:2 PSM. GNEC staging was classified according to World Health Organization (WHO) gastroenteropancreatic-neuroendocrine tumor (GEP-NET) classification criteria (2010) \[[@R20]\], and GAC was classified by Union for International Cancer Control (UICC) classification criteria (2010, 7th edition) \[[@R21]\]. The GNEC inclusion criteria used the following parameters: (1) a postoperative pathological diagnosis of GNEC after 2010 and (2) a postoperative pathological diagnosis of GNEC with neuroendocrine differentiation before 2010 and then re-diagnosis as GNEC. The GAC inclusive criteria used the following parameters: (1) those whose endoscopic biopsy results and postoperative pathological results were all GAC and (2) those without distant metastasis, as assessed by preoperative examinations. The exclusion criteria used the following parameters: (1) patients receiving neo-adjuvant chemotherapy; (2) intraperitoneal dissemination or distant metastasis observed during surgery; (3) incomplete data for pathological diagnosis; (4) combination with other tumor; or (5) postoperative pathology diagnosed with non-R0 resection. The study was approved by the ethics committee of the Fujian Medical University Union Hospital. Written consent was provided by the patients for their information and specimens to be stored in the hospital database and used for research.

Variables and definitions {#s4_2}
-------------------------

GNEC diagnosis criteria: The diagnosis was mainly based on morphological features of hematoxylin-eosin (HE) staining and specific neuroendocrine markers of immunohistochemistry, including chromogranin A (CGA), synaptophysin (SYN), neuro-specific enolase (NSE) and CD56. Two experienced pathologists evaluated the patient samples (4-μm paraffin sections, HE staining) and confirmed the pathological data of the patients. The projects included immunohistochemical results, mitotic count and tumor cell types. GNEC (WHO G3) was defined as a simple neuroendocrine carcinoma (Ki-67 labeling index \> 20% or mitotic count \> 20/HPF) or mixed gonadal neuroendocrine carcinoma (Ki-67 labeling index \> 20% or mitotic count \> 20/HPF) \[[@R22]\]. OS was recorded from the operation time to the last follow-up, date of death or the deadline of the follow-up database (such as lost to follow-up or other causes of death). RFS was the time from the first diagnosis to the initial recurrence. PRS was the time from the initial recurrence to the date of death. The following definitions of recurrent tumors were utilized: (1) local recurrence - gastric stump or anastomotic recurrence, metastasis to lymph nodes around the stomach; (2) hematogenous metastasis - metastasis of remote organs (e.g., the liver, lung, brain, bone); (3) peritoneal recurrence - a tumor derived from the peritoneum or ovary; or (4) metastasis to distant lymph nodes - metastasis to periaortic lymph nodes or lymph nodes outside the abdominal cavity \[[@R23]\]. N0 indicated no lymph node metastasis, and N+ indicated lymph node metastasis.

Therapeutic approach {#s4_3}
--------------------

Surgical procedure: the patients were subjected to intravenous-inhalation combined anesthesia and signed operation consent documents. The surgical methods, including radical total gastrectomy, radical distal gastrectomy and proximal gastrectomy, were selected depending on the tumor location. Lymph node dissection was performed according to Japanese gastric cancer treatment guidelines (13th edition) \[[@R24]\].

Postoperative adjuvant chemotherapy: patients at stage II or above received chemotherapy based on 5-Fu. The scheme of postoperative adjuvant chemotherapy was Xeloda/S-1 combined oxaliplatin 2-4 weeks after surgery, with a 3-week intermission and a total course of 6 cycles.

Treatment for recurrence: patients without postoperative adjuvant chemotherapy received chemotherapy based on 5-Fu plus platinum. Patients with recurrence after postoperative adjuvant chemotherapy were treated with chemotherapy based on 5-Fu plus Taxol or Xeloda/S-1 plus platinum/Taxol.

Follow-up {#s4_4}
---------

All patients were systematically followed up every 3 months for the first two years and at 6-month intervals thereafter *via* outpatient serviced, visits, letter or telephone. All patients were routinely subject to physical examinations, laboratory tests (e.g., CA19-9, CA72-4, CEA), chest radiography, abdominal CT scan and abdomen ultrasound every year.

Statistical analysis {#s4_5}
--------------------

Statistical analyses were performed using SPSS 18.0 (SPSS Inc, Chicago, IL, USA). Continuous variables were assessed by $\overline{x}$ s. Categorical variables were calculated using the Pearson *χ2* test or Fisher\'s test. Survival curves were explored using the Kaplan-Meier method. Comparison of survival rates was performed using the log-rank test. Multivariate analysis of prognostic factors was calculated using Cox proportional hazard models. Statistical significance was set as *p*-values \< 0.05.
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